Literature DB >> 30210147

Change in Management of Status Epilepticus With the Addition of Neurointensivist-Led Neurocritical Care Team at a Rural Academic Medical Center.

Julianne Yeary1, Jeffrey Garavaglia1, Richard McKnight1, Matthew Smith1.   

Abstract

Learning Objective: Status epilepticus (SE) is continuous clinical and/or electrographic seizures lasting 5 minutes or more without recovery and carries a high mortality. Medication management varies by institution, as well as administration, combination of antiepileptic drugs (AEDs), and dosing.
Methods: Single-center retrospective review of medication management of SE patients admitted to West Virginia University Hospital before and after neurointensivist implemented guidelines. Patients admitted between January 2012 and June 2014 were grouped in the prior to neurointensivist group (pre-NI) and patients admitted between July 2014 and June 2016 were grouped in the postneurointensivist group (post-NI). Baseline demographics, hospital, intensive care unit (ICU), and ventilator length of stay were recorded. Medications reviewed included number of AEDs and maximum dose of lorazepam, phenytoin, levetiracetam, and lacosamide. Outcomes included number of continuous infusions of either midazolam or propofol at seizure suppression doses as well as pentobarbital, phenobarbital, or ketamine, and need for vasopressor use.
Results: Of the 74 patients included, the pre-NI group (n = 40) utilized more AEDs (6 vs 4) compared with the post-NI group (n = 34). The pre-NI group had less midazolam continuous infusions meeting seizure suppression doses (8 vs 9), but higher average doses (49 vs 27 mg/h) compared with the post-NI group. More patients in the pre-NI group were on propofol seizure suppression doses (15 vs 10) and phenobarbital continuous infusions (11 vs 2) than the post-NI group. Patients had less vasopressor use in the post-NI group than the pre-NI group (11 vs 23). Frequency and dosing of lorazepam, phenytoin, levetiracetam, and lacosamide were similar between the 2 groups. Ventilator use, hospital, and ICU length of stay were also similar between groups. Discussion: Implementation of a neurointensivist and medication guidelines resulted in fewer AEDs and less vasopressor use in the management of SE. Midazolam use was slightly higher in the post-NI group but at lower doses overall.

Entities:  

Keywords:  anticonvulsants; clinical services; critical care; disease management; drug/medical use evaluation; neurology

Year:  2018        PMID: 30210147      PMCID: PMC6130113          DOI: 10.1177/0018578717750094

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  8 in total

1.  Mortality Associated with Status Epilepticus.

Authors:  Jane G. Boggs
Journal:  Epilepsy Curr       Date:  2004-01       Impact factor: 7.500

2.  Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.

Authors:  Tracy Glauser; Shlomo Shinnar; David Gloss; Brian Alldredge; Ravindra Arya; Jacquelyn Bainbridge; Mary Bare; Thomas Bleck; W Edwin Dodson; Lisa Garrity; Andy Jagoda; Daniel Lowenstein; John Pellock; James Riviello; Edward Sloan; David M Treiman
Journal:  Epilepsy Curr       Date:  2016 Jan-Feb       Impact factor: 7.500

Review 3.  Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus.

Authors:  Francesco Brigo; Nicola Bragazzi; Raffaele Nardone; Eugen Trinka
Journal:  Epilepsy Behav       Date:  2016-10-11       Impact factor: 2.937

4.  Guidelines for the evaluation and management of status epilepticus.

Authors:  Gretchen M Brophy; Rodney Bell; Jan Claassen; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Suzette M Laroche; James J Riviello; Lori Shutter; Michael R Sperling; David M Treiman; Paul M Vespa
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

5.  Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study.

Authors:  Raoul Sutter; Stephan Marsch; Stephan Rüegg
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

Review 6.  Ketamine for the treatment of refractory status epilepticus.

Authors:  Yao Fang; Xuefeng Wang
Journal:  Seizure       Date:  2015-05-19       Impact factor: 3.184

7.  Generalized convulsive status epilepticus: causes, therapy, and outcome in 346 patients.

Authors:  F B Scholtes; W O Renier; H Meinardi
Journal:  Epilepsia       Date:  1994 Sep-Oct       Impact factor: 5.864

8.  Practice variations in the management of status epilepticus.

Authors:  Aaron M Cook; Amber Castle; Amy Green; Christine Lesch; Christopher Morrison; Denise Rhoney; Dennis Parker; Eljim Tesoro; Gretchen Brophy; Haley Goodwin; Jane Gokun; Jason Makii; Karen McAllen; Kathleen Bledsoe; Kiranpal Sangha; Kyle Weant; Norah Liang; Teresa Murphy-Human
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.